thus the importance of understanding the MOA this could validate a lot of the claims that were rejected. So basically MOA not required for Pharma or FDA but potentially for a patent.
Side note, they didn’t agree that Bisantrene self rescues but rather it was just heart safe to begin with. Thus more work for Dr Jensen to firm up.
Also ARA-C previously released so prior art unless something more novel is identified. And more proof to expand to all anthracyclines and herceptin per the triangle report.
General Comments / Chat, page-7706
-
- There are more pages in this discussion • 3,523 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |